| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DOCK1 |
| Uniprot No | Q14185 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DOCK1重组蛋白的参考文献示例(内容为模拟虚构，仅供参考格式)：
---
1. **"Expression and Purification of Functional DOCK1 Recombinant Protein in Insect Cells"**
*Smith, J. et al. (2015)*
摘要：本研究利用杆状病毒-昆虫细胞系统成功表达了具有生物活性的DOCK1重组蛋白，并通过亲和层析纯化。功能实验表明，纯化的DOCK1能激活Rac1 GTPase，为研究其分子机制提供了工具。
2. **"Structural Insights into DOCK1-Mediated Rac Activation Using Cryo-EM"**
*Zhang, Y. et al. (2018)*
摘要：通过冷冻电镜解析了重组DOCK1蛋白与Rac1的复合物结构，揭示了DOCK1的DHR2结构域介导的鸟苷酸交换机制，阐明了其特异性激活Rac的分子基础。
3. **"DOCK1 Recombinant Protein Enhances Cancer Cell Migration in vitro"**
*Lee, H. et al. (2016)*
摘要：利用大肠杆菌表达的重组DOCK1蛋白处理乳腺癌细胞，发现其通过Rac1信号通路显著促进细胞迁移和侵袭，提示DOCK1在肿瘤转移中的潜在作用。
4. **"Development of a High-Throughput Assay for DOCK1 GEF Activity"**
*Johnson, R. et al. (2020)*
摘要：构建了基于荧光共振能量转移(FRET)的检测体系，利用纯化的DOCK1重组蛋白高通量筛选其鸟苷酸交换因子(GEF)活性抑制剂，为药物开发提供平台。
---
注：以上文献为示例性内容，实际引用时需根据真实论文调整。建议通过PubMed、Google Scholar等平台以关键词“DOCK1 recombinant protein”或“DOCK1 purification/function”检索最新研究。
DOCK1 (Dedicator of Cytokinesis 1) is a member of the DOCK protein family, which functions as guanine nucleotide exchange factors (GEFs) for Rho GTPases, particularly Cdc42. These proteins play pivotal roles in regulating cytoskeletal dynamics, cell migration, and intracellular signaling. DOCK1. specifically, is categorized under the DOCK-A subfamily and is known to activate Cdc42 by promoting the exchange of GDP for GTP, thereby modulating downstream pathways involved in cell adhesion, polarization, and motility. Its structure includes conserved DHR-1 (CZH1) and DHR-2 (CZH2) domains, with the latter directly mediating GEF activity.
Originally identified for its role in immune responses, DOCK1 is critical in immune cell trafficking, phagocytosis, and T-cell activation. Beyond immunology, it influences neuronal development, epithelial morphogenesis, and cancer progression. Aberrant DOCK1 expression or activity has been linked to pathological conditions, including metastatic cancers (e.g., breast cancer, melanoma) and neurological disorders. For instance, DOCK1 overexpression in tumors often correlates with enhanced cell invasion and poor prognosis, highlighting its potential as a therapeutic target.
Recombinant DOCK1 proteins are engineered to study its biochemical functions, screen inhibitors, or dissect signaling cascades. These proteins are typically produced in bacterial (e.g., *E. coli*) or mammalian expression systems, often fused with tags (e.g., His, GST) for purification and detection. Researchers utilize recombinant DOCK1 in *in vitro* assays to analyze GTPase binding, GEF activity, or protein-protein interactions. Additionally, they serve as antigens for antibody development or tools in high-throughput drug discovery platforms. Understanding DOCK1’s molecular mechanisms through recombinant proteins continues to advance insights into cellular physiology and disease intervention strategies.
×
